Floatz logo

ETOPOSIDE

HER2/Neu Negative

Fudan UniversitySmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the HER2/Neu Negative cohort.

Asset / SponsorPhaseRating
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Pembrolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 2BBB
Inno-206
Roswell Park Cancer Institute
Phase 3BB
Durvalumab
National Cancer Institute (NCI)
Phase 3BB
Zoladex
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

ETOPOSIDE is also rated in:

acute megakaryoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute myeloblastic leukemia with maturationDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →